Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany
- PMID: 38211602
- DOI: 10.1016/S1473-3099(23)00783-1
Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany
Conflict of interest statement
MH, AK, IN, and SP conducted contract research (testing of vaccinee serum samples for neutralising activity against SARS-CoV-2) for Valneva unrelated to this work. GMNB served as adviser for Moderna. SP served as adviser for BioNTech, unrelated to this work, AD-J served as an adviser for Pfizer unrelated to this work. All other authors declare no competing interests. GMNB and AD-J. acknowledge funding (Niedersächsisches Ministerium für Wissenschaft und Kultur; 14-76103-184 and COFONI Network, project 4LZF23). GMNB acknowledges funding by the European Regional Development Fund (ZW7-85151373) and AD-J acknowledges funding by European Social Fund (ZAM5-87006761). SP acknowledges funding by the EU project UNDINE (grant agreement number 101057100), the Ministry for Science and Culture of Lower Saxony (Niedersächsisches Ministerium für Wissenschaft und Kultur; 14-76103-184; COFONI Network, projects 7FF22, 6FF22, 10FF22), and the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; PO 716/11-1). The funding sources had no role in the design and execution of the study, the writing of the manuscript and the decision to submit the manuscript for publication. The authors did not receive payment by a pharmaceutical company or other agency to write the publication. The authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication. AC and MH are joint first authors, and GMNB and AD-J are co-senior authors.
Similar articles
-
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.Lancet Infect Dis. 2024 Jan;24(1):e1-e3. doi: 10.1016/S1473-3099(23)00690-4. Epub 2023 Nov 20. Lancet Infect Dis. 2024. PMID: 37995739 No abstract available.
-
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.Nat Commun. 2023 Sep 27;14(1):6041. doi: 10.1038/s41467-023-41678-9. Nat Commun. 2023. PMID: 37758707 Free PMC article.
-
Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study.BMC Nephrol. 2023 May 30;24(1):151. doi: 10.1186/s12882-023-03218-x. BMC Nephrol. 2023. PMID: 37248445 Free PMC article.
-
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.Lancet Infect Dis. 2024 Feb;24(2):e80-e81. doi: 10.1016/S1473-3099(23)00779-X. Epub 2024 Jan 5. Lancet Infect Dis. 2024. PMID: 38190833 No abstract available.
-
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.Kidney Int. 2022 May;101(5):883-894. doi: 10.1016/j.kint.2022.01.022. Epub 2022 Feb 14. Kidney Int. 2022. PMID: 35176326 Free PMC article. Review.
Cited by
-
Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients.Viruses. 2024 Dec 19;16(12):1942. doi: 10.3390/v16121942. Viruses. 2024. PMID: 39772248 Free PMC article.
-
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial.Trials. 2024 Jul 17;25(1):485. doi: 10.1186/s13063-024-08315-2. Trials. 2024. PMID: 39020446 Free PMC article.
-
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses.EBioMedicine. 2025 Mar;113:105577. doi: 10.1016/j.ebiom.2025.105577. Epub 2025 Feb 4. EBioMedicine. 2025. PMID: 39908650 Free PMC article.
-
The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells.Front Immunol. 2025 Mar 12;16:1513175. doi: 10.3389/fimmu.2025.1513175. eCollection 2025. Front Immunol. 2025. PMID: 40145092 Free PMC article.
-
Impaired Hepatitis B and COVID-19 vaccination responses show strong concordance in hemodialysis patients with end stage renal disease.Eur J Med Res. 2025 Jan 16;30(1):34. doi: 10.1186/s40001-025-02274-3. Eur J Med Res. 2025. PMID: 39819737 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical